Stockscreener 앱 받기
84.62
2.46%
2.03
시간 외 거래:
84.62
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
Levels Update: What hedge funds are buying Rhythm Pharmaceuticals IncMarket Rally & Accurate Entry/Exit Alerts - baoquankhu1.vn
Rhythm wins US nod for Imcivree in rare hypothalamic obesity - The Pharma Letter
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - BioSpace
Tech Rally: Is Rhythm Pharmaceuticals Inc. gaining market share2026 PreEarnings & Technical Pattern Based Signals - baoquankhu1.vn
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setme - The National Law Review
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity - Yahoo Finance
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch - Yahoo Finance
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide - MarketBeat
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' - Investor's Business Daily
Rhythm Pharmaceuticals (RYTM) Receives Buy Rating and Raised Pri - GuruFocus
RYTM: Citigroup Raises Price Target on Rhythm Pharmaceuticals | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Expands IMCIVREE Distribution Part - GuruFocus
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide - Insider Monkey
RYTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap UpHere's What Happened - MarketBeat
FDA Approves IMCIVREE (Setmelanotide) as First Therapy for Acquired Hypothalamic Obesity in Adults and Children 4+ - Minichart
**Rhythm Pharmaceuticals Surges with Significant Market Moves After FDA Expansion** - StocksToTrade
Rhythm Pharmaceuticals jumps as investors focus on FDA decision timing for hypothalamic obesity label expansion - Quiver Quantitative
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA - TipRanks
Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy - TipRanks
Why Is Rhythm Pharma Stock Gaining Friday?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% placebo‑adjusted BMI - TradingView
Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN) - Benzinga
Rhythm Pharmaceuticals (Nasdaq: RYTM) gains FDA OK for IMCIVREE in acquired hypothalamic obesity - Stock Titan
Rhythm obesity drug wins broader use from FDA - BioPharma Dive
HC Wainwright Analysts Lower Earnings Estimates for RYTM - MarketBeat
After setback, Rhythm gets good news on Imcivree from FDA - pharmaphorum
Rhythm Pharmaceuticals (RYTM) Gains on FDA Approval for Expanded Use of Imcivree - GuruFocus
Rhythm Pharmaceuticals stock jumps on FDA approval - Investing.com
Rhythm Pharmaceuticals stock jumps on FDA approval By Investing.com - Investing.com Canada
After receiving approval from the U.S. Food and Drug Administration (FDA) for its brain injury-related obesity treatment, Rhythm Pharmaceuticals Inc. (RYTM) shares surged 7.4% in pre-market trading. - Bitget
Rhythm Pharma higher after FDA label expansion for lead drug - Seeking Alpha
Rhythm's therapy becomes first FDA-approved treatment for brain damage-related obesity - Reuters
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals - Indian Pharma Post
Is First FDA‑Approved IMCIVREE Use In Hypothalamic Obesity Altering The Investment Case For Rhythm Pharmaceuticals (RYTM)? - Sahm
5 Most Promising Stocks Under $100 to Buy - Insider Monkey
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - The Manila Times
Rhythm Awaits FDA Decision On Expanded Use Of Imcivree In Hypothalamic Obesity - RTTNews
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - MSN
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism - Insider Monkey
H.C. Wainwright cuts Rhythm Pharmaceuticals stock price target on trial miss - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) expected to beat earnings estimates: Should you buy? - MSN
HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating - TipRanks
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss - Citeline News & Insights
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Weakness And Strong Long Term Returns - Yahoo Finance
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its 4x Three Year Surge? - simplywall.st
Wall Street Recap: Can Rhythm Pharmaceuticals Inc ride the EV waveSwing Trade & Daily Profit Maximizing Tips - baoquankhu1.vn
Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote, News & History - Benzinga
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaini - GuruFocus
Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat - Investor's Business Daily
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup - MarketBeat
Post-Emanate, Rhythm’s next Imcivree news aHO lot better? - BioWorld MedTech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $130.00 at Royal Bank Of Canada - MarketBeat
1.82%
자본화:
|
볼륨(24시간):